(Reuters) - Total annual sales of the drug are about $2.8 billion,
Israel-based Teva said. Once one of Pfizer's biggest selling
drugs, an incoming flood of generics is expected to eat
dramatically into sales.
Rival generic drugmaker Mylan Laboratories Inc. in
March launched a generic form of the medicine, known
generically as amlodipine, after a federal appeals court
declared some of Pfizer's patent claims invalid.
Read more at Reuters.com Government Filings News
Israel-based Teva said. Once one of Pfizer's biggest selling
drugs, an incoming flood of generics is expected to eat
dramatically into sales.
Rival generic drugmaker Mylan Laboratories Inc. in
March launched a generic form of the medicine, known
generically as amlodipine, after a federal appeals court
declared some of Pfizer's patent claims invalid.
Read more at Reuters.com Government Filings News
No comments:
Post a Comment